Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only postpartum depression pill approved in the United States, the companies said on Monday.

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential. Read my analysis on this acquisition.

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.